Your SlideShare is downloading. ×
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
113342211
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

113342211

319

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
319
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. ATHENA Trial
    ATHENA Trial(A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter)
    Presented at Heart Rhythm 2008 in San Francisco, USA
    Presented by Stefan H. Hohnloser, MD
    Copyleft Clinical Trial Results. You Must Redistribute Slides
  • 2. ATHENA Trial: Background
    Atrial fibrillation (AF) impairs patients’ lives, leading to increased risks of cardiovascular complications.
    Over the course of 20 years of clinical drug trials in AF no drug has demonstrated a significant reduction in the risk of cardiac death.
    ATHENA set out to evaluate the effect of Multaq® (dronedarone), a multi-channel blocker with anti-adrenergic properties, on a composite primary endpoint of all-cause mortality and cardiovascular hospitalization in patients with AF.
    JCE 2008; 19.1/Heart Rhythm 2008
  • 3. ATHENA Trial: Dronedarone
    Dronedarone (Multaq®) manufactured by Sanofi-aventis is a new multi-channel blocker that affects the calcium, potassium and sodium channels and has anti-adrenergic properties.
    Unlike amiodarone, this drug does not contain iodine radical and hence does not result in adverse effects on thyroid and lung functions.
    JCE 2008; 19.1/Heart Rhythm 2008
  • 4. ATHENA Trial: Study Design
    4,628 patients >75 years with atrial fibrillation or 70-75 years with atrial fibrillation and at least one additional cardiovascular risk factor prior to randomization.
    Double blind. Randomized. Placebo controlled. International multicenter. Mean follow-up 21 months.
    R
    Multaq® (dronedarone)
    400 mg BID
    Placebo
    12-30 mos. follow-up
    • Primary Endpoint: composite of all-cause mortality combined with cardiovascular hospitalization
    • 5. Secondary Endpoint: death from any cause, cardiovascular death, hospitalization for cardiovascular reasons
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 6. ATHENA Trial: Inclusion Criteria
    ≥75 yrs with or without additional risk factors
    ≥70 yrs with at least one of the following risk factors: arterial hypertension (ongoing therapy with at least two antihypertensive drugs of different classes), diabetes mellitus, prior stroke or transient ischemic attack or systemic embolism, left atrium diameter ≥ 50 mm by M-mode echocardiography, LVEF < 0.40 by 2D-echocardiography.
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 7. ATHENA Trial: Inclusion Criteria Cont.
    Availability of one 12-lead ECG within the last 6 months, indicating prior or current AF/A flutter
    Access to a second 12-lead ECG within the last 6 months showing prior or current SR
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 8. ATHENA Trial: Exclusion Criteria
    Presence of one of the following cardiac conditions:
    Permanent AF
    Unstable hemodynamic situation (i.e., recently decompensated heart failure)
    Congestive heart failure NYHA class IV
    Planned major non-cardiac or cardiac surgery
    Acute myocarditis
    Bradycardia < 50 bpm and/or a PR interval > 0.28 seconds
    Significant sinus node disease in the past, if not treated with a pacemaker
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 9. ATHENA Trial: Exclusion Criteria cont.
    Refusal or inability to give informed consent
    Any non-cardiac severe illness limiting life expectancy
    Pregnancy and breast feeding
    Women of child-bearing potential without adequate birth control
    Participation in another clinical trial
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 10. ATHENA Trial: Exclusion Criteria cont.
    A calculated GFR at baseline < 10mL/min using the Cockroft Gault formula
    Potassium level < 3.5 mmol/L if not corrected
    Need for concomitant medication prohibited within ATHENA (i.e., other antiarrhythmic drugs of Vaughan-Williams class I or III)
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 11. ATHENA Trial: Baseline Characteristics
    *AF at baseline: according to the stratification factor at randomization.
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1 /Heart Rhythm 2008
  • 12. ATHENA Trial: Baseline Characteristics
    **Structural heart disease: coronary heart disease and/or ischemic dilated cardiomyopathy and/or nonischemic dilated cardiomyopathy and/or rheumatic valvular heart disease and/or nonrheumatic valvular heart disease and/or hypertrophic cardiomyopathy and/or history of congestive heart failure and/or left ventricular ejection fraction (LVEF) < 45%.
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 13. ATHENA Trial: Baseline Characteristics
    ***Lone atrial fibrillation: patients without hypertension and without structural heart disease.
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 14. ATHENA Trial: Primary Endpoint Results
    Multaq® (dronedarone) decreased the risk of cardiovascular hospitalizations or death from any cause by 24% (p<0.001).
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 15. ATHENA Trial: Secondary Endpoint Results
    Compared to placebo, Multaq® (dronedarone) significantly decreased the risk of cardiovascular death by 30% (p=0.034).
    Multaq® (dronedarone) was associated with numerically fewer deaths from any cause (16%, p=0.17).
    First cardiovascular hospitalization was reduced by 25% (p=<0.001).
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 16. ATHENA Trial: Other Outcomes
    Death from arrhythmias was reduced by 45% (p=0.01) when patients were treated with Multaq® (dronedarone).
    Multaq® (dronedarone) demonstrated a lower risk of pro-arrhythmia than placebo and no excess of hospitalizations for congestive heart failure.
    The rate of study drug discontinuation was similar between the two study arms.
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 17. ATHENA Trial: Adverse Events
    • There was a higher frequency of reported gastro-intestinal complications in the Multaq® (dronedarone) group than in the placebo arm.
    Gastro-intestinal Effects (%)
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 18. ATHENA Trial: Adverse Events
    • Multaq® (dronedarone) was associated with a more frequent occurrence of skin disorders as compared to placebo.
    Skin disorders (mainly rash) (%)
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 19. ATHENA Trial: Adverse Events
    • Patients treated with Multaq® (dronedarone) demonstrated increased serum creatinine more frequently than those given placebo.
    Increased Blood Creatinine (%)
    Copyleft Clinical Trial Results. You Must Redistribute Slides
    JCE 2008; 19.1/Heart Rhythm 2008
  • 20. ATHENA Trial: Limitations
    Future trials should consider patients under 75 years of age without additional cardiovascular risk factors and those with decompensated heart failure.
    The exclusion of these patients from this study limits the applicability of the results.
    JCE 2008; 19.1/Heart Rhythm 2008
  • 21. ATHENA Trial: Summary
    Multaq® (dronedarone) has been discovered as the first safe drug to benefit patients with atrial fibrillation.
    Findings include decreased rates of cardiovascular hospitalization and mortality.
    JCE 2008; 19.1/Heart Rhythm 2008

×